Source: New York Post
Hims & Hers announced they are scrapping plans to sell a compounded version of the weight loss drug Wegovy after federal regulators vowed to take action against the telehealth provider. “Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” the company said.
Aller á la Source
Nouvelles connexes
